Dignitana announces American M – GuruFocus.com

STOCKHOLM, June 16, 2022 /PRNewswire/ — Dignitana AB experiences {that a} coverage in help of scalp cooling to reduce hair loss from chemotherapy induced alopecia was introduced as a decision and reaffirmed by the Home of Delegates of the American Medical Affiliation (AMA) on the group’s Annual Assembly in Chicago this week.

The coverage, Resolution 707: Insurance Coverage for Scalp Cooling (Cold Cap) Therapy, states that the AMA shall “advocate for and search by way of laws and/or regulation, common insurance coverage protection for Scalp Cooling (Chilly Cap) Remedy” and directs that the AMA “work with client and advocacy teams to problem insurers on medical necessity denials for Scalp Cooling (Chilly Cap) Remedy and encourage appeals to unbiased third-party reviewers.”

“Reimbursement for scalp cooling is a prime precedence for Dignitana, and we admire this sign of help from the most important doctor group in the USA,” stated Dignitana CEO Catarina Mård Löwenadler. “Scalp cooling is evidence-based, really helpful by the National Comprehensive Cancer Network® (NCCN), and now supported by the AMA as properly. Scalp cooling ought to develop into customary of care with common insurance coverage protection in order that any most cancers affected person who needs to reduce hair loss from chemotherapy has entry to this life-changing remedy.”

The House of Delegates (HOD) is the legislative and policy-making physique of the American Medical Affiliation. State medical associations and nationwide medical specialty societies (such because the American Society of Scientific Oncology) are represented within the HOD together with different medical organizations.

Decision 707 was launched to the AMA by the Medical Society of the State of New York (MSSSNY) after that group approved a similar resolution in Could 2021.

In reaffirming current policy in relation to Decision 707, the AMA referenced six present AMA insurance policies that lend help to protection of this remedy: Methods to Handle Rising Well being Care Prices H-155.960; Aligning Scientific and Monetary Incentives for Excessive-Worth Care D-185.979; Medical Necessity and Utilization Evaluation H-320.942; Managed Care H-285.998; Medical Necessity Determinations H-320.995; and Standing Report on the Uninsured H-185.964.

Patented in 1998 and FDA cleared since 2015, The DigniCap® Scalp Cooling System provides sufferers the flexibility to reduce hair loss throughout chemotherapy with clinically superior efficacy, affected person consolation and demonstrated security. DigniCap is on the market at about 300 most cancers facilities within the U.S. and in 40 nations worldwide.

CONTACT:

For Extra Data Contact

Melissa Bourestom, Chief Communications Officer, [email protected] +1 469-518-5031

This data was delivered to you by Cision http://news.cision.com

https://news.cision.com/dignitana-ab/r/dignitana-announces-american-medical-association-reaffirms-policy-supporting-scalp-cooling,c3586951

The next information can be found for obtain:

View authentic content material:https://www.prnewswire.com/news-releases/dignitana-announces-american-medical-association-reaffirms-policy-supporting-scalp-cooling-301569653.html

SOURCE Dignitana AB